AcelRx Pharmaceuticals, Inc. (ACRX)
| Market Cap | 74.90M |
| Revenue (ttm) | 3.55M |
| Net Income (ttm) | -36.10M |
| Shares Out | 119.32M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | 3.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 599,343 |
| Open | 0.580 |
| Previous Close | 0.565 |
| Day's Range | 0.567 - 0.628 |
| 52-Week Range | 0.540 - 2.940 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 4.17 (+564.3%) |
| Earnings Date | Nov 15, 2021 |
About ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 4.17, which is an increase of 564.33% from the latest price.
News
AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies fo...
AcelRx To Acquire Lowell For $32M, Announces Capital Raise Of $14M
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to acquire privately-held Lowell Therapeutics Inc for approximately $32.5 million. The deal consideration includes approximately $26 million of conti...
AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering
HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...
AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results
HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021
HAYWARD, Calif., Nov. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results befor...
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative t...
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient...
HAYWARD, Calif., Aug. 30, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery ...
HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021
Analysts say these are penny stocks to buy. Do you agree?
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results
HAYWARD, Calif., Aug. 16, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm
New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding po...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals,...
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of i...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. ...
Los Angeles, California--(Newsfile Corp. - August 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...
ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Ac...
New York, New York--(Newsfile Corp. - August 9, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...
ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors w...
New York, New York--(Newsfile Corp. - August 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) betwee...
AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021
HAYWARD, Calif., Aug. 9, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after...
ACRX Final Deadline Monday: Rosen, a Trusted and Leading Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors ...
New York, New York--(Newsfile Corp. - August 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) betwee...
DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals...
Los Angeles, California--(Newsfile Corp. - August 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pha...
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceutical...
Los Angeles, California--(Newsfile Corp. - August 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...
MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceutic...
Los Angeles, California--(Newsfile Corp. - August 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...
ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class...
New York, New York--(Newsfile Corp. - August 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...
ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Sec...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...